A Massachusetts biotech that has been flying under the radar since its foundation in 2021, Treeline Biosciences, has emerged with $200 million in funding for a trio of cancer drugs. The ...
Beijing biotech Sironax has closed a whopping $200 million second-round financing that shows investors still have a desire to back companies working on RIPK1 inhibitors despite setbacks for GSK in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback